Though early AFP response was associated with higher treatment efficacy of ICIs for advanced HCC 38, to date, the most extensively studied predictive biomarkers for efficacy of ICI therapy are TMB and PD-L1 expression 33. This evidence concerns the gene CD274 and hepatocellular carcinoma.